Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients

Amir Fathi • 9 Jun 2016
EHA 2016
Acute Myeloid Leukemia

Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which produces high remission rates among older patients with AML at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

More from Amir Fathi

1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023
2:04
Hot topics in the AML space: menin inhibitors
Amir Fathi • 21 Nov 2023
1:44
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi • 21 Nov 2023
1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals